Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC-MS/MS.


Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
10 Sep 2020
Historique:
received: 30 12 2019
revised: 01 07 2020
accepted: 05 07 2020
pubmed: 14 7 2020
medline: 22 6 2021
entrez: 14 7 2020
Statut: ppublish

Résumé

We developed a high-performance liquid chromatography mass spectrometry method for quantitating iohexol in 50 μL human plasma. After acetonitrile protein precipitation, chromatographic separation was achieved with a Shodex Asahipak NH2P-50 2D (5 μm, 2 × 150 mm) column and a gradient of 0.1 % formic acid in acetonitrile and 0.1 % formic acid in water over a 10 min run time. Mass spectrometric detection was performed on a Micromass Quatromicro triple-stage bench-top mass spectrometer with electrospray, positive-mode ionization. The assay was linear from 1 to 500 μg/mL for iohexol, proved to be accurate (101.3-102.1 %) and precise (<3.4 %CV), and fulfilled Food and Drug Administration (FDA) criteria for bioanalytical method validation. Recovery from plasma was 53.1-64.2 % and matrix effect was trivial (-3.4 to -1.3 %). Plasma freeze thaw stability (97.4-99.4 %), stability for 5 months at -80 °C (95.5-103.3 %), and stability for 4 h at room temperature (100.6-103.3 %) were all acceptable. This validated assay using a deuterated internal standard will be an important tool in measuring iohexol clearance and determining glomerular filtration rate (GFR) in patients.

Identifiants

pubmed: 32659569
pii: S0731-7085(20)31350-9
doi: 10.1016/j.jpba.2020.113464
pmc: PMC7484441
mid: NIHMS1610160
pii:
doi:

Substances chimiques

Iohexol 4419T9MX03

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113464

Subventions

Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211241
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA247643
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186690
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors report no declarations of interest.

Références

Clin J Am Soc Nephrol. 2019 Apr 5;14(4):587-595
pubmed: 30890575
Clin Chim Acta. 2016 Dec 1;463:96-102
pubmed: 27756544
Am J Kidney Dis. 2013 Jan;61(1):57-66
pubmed: 22889713
Invest Radiol. 1983 Mar-Apr;18(2):177-82
pubmed: 6408018
Methods Mol Biol. 2009;466:61-72
pubmed: 19148601
Invest Radiol. 1988 Sep;23 Suppl 1:S106-9
pubmed: 3198329
J Am Soc Nephrol. 1995 Aug;6(2):257-63
pubmed: 7579093
Am J Kidney Dis. 2018 Feb;71(2):163-165
pubmed: 29217306
J Sep Sci. 2006 Aug;29(12):1784-821
pubmed: 16970185
J Lab Clin Med. 1984 Dec;104(6):955-61
pubmed: 6438261
Clin Chem. 2009 Jun;55(6):1196-202
pubmed: 19359533
J Pharm Biomed Anal. 2017 May 10;138:197-205
pubmed: 28219796

Auteurs

Julianne L Holleran (JL)

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States. Electronic address: HollJL@UPMC.EDU.

Robert A Parise (RA)

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States. Electronic address: parisera@upmc.edu.

Jianxia Guo (J)

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States. Electronic address: guoxjx@UPMC.EDU.

Brian F Kiesel (BF)

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States. Electronic address: kieselb@upmc.edu.

Sarah E Taylor (SE)

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Medicine, University of Pittsburgh-Magee Women's Hospital, Pittsburgh, PA, United States. Electronic address: taylorse2@upmc.edu.

S Percy Ivy (SP)

Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States. Electronic address: ivyp@ctep.nci.nih.gov.

Edward Chu (E)

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. Electronic address: chue2@upmc.edu.

Jan H Beumer (JH)

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. Electronic address: beumerj@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH